We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BASFY adds Lavergy L Pace, C Care, and A Star to its liquid enzyme portfolio for home care markets.
New enzymes target fat removal, fabric care, and starch stain cleaning at low temperatures.
BASFY builds on existing Lavergy products, boosting its position in sustainable deep cleaning.
BASF SE (BASFY - Free Report) has expanded its product portfolio of liquid enzymes to better serve the home care and I&I industry. With years of expertise, BASF has successfully integrated high-quality and high-performance enzymes into its product line, while ensuring sustainability and deep cleaning solutions. BASF has enhanced its range of liquid enzymes through the addition of lipase, cellulase and amylase offerings.
Building on its Lavergy product line, BASF has launched Lavergy L Pace, Lavergy C Care and Lavergy A Star. A liquid lipase product, Lavergy L Pace, has superior fat and oil stain removal ability at low temperatures. Lavergy C Care, a liquid care cellulase product, offers excellent fuzz and pill removal, best suited for cotton and cotton blend fabrics. The Lavergy A Star amylase biodegradable enzyme solution is effective in removing starch stains, offering a deeper clean.
BASF had already launched products like Lavergy M Ace, Lavergy C Bright and Lavergy Pro, building on its enzyme portfolio. With its in-depth technical know-how and innovation pipeline, BASF has positioned itself as one of the leaders in this industry.
BASFY stock has gained 9.7% over the past year compared with the industry’s 15.1% decline.
The Zacks Consensus Estimate for RGLD’s current-year earnings is pegged at $7.47 per share, indicating a 42% year-over-year increase.Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 9%. RGLD’s shares have gained 18.7% in the past year.
The Zacks Consensus Estimate for CDE’s current-year earnings is pegged at 69 cents per share, implying a 283.3% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing once, with an average surprise of 136.2%.
The Zacks Consensus Estimate for CRS’ fiscal 2025 earnings is pegged at $7.28 per share, indicating a rise of 53.6% from year-ago levels. The company’s earnings beat the consensus estimate in each of the trailing four quarters. Its shares have gained 150.6% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BASFY Expands Liquid Enzyme Portfolio, Boosts Laundry Solutions
Key Takeaways
BASF SE (BASFY - Free Report) has expanded its product portfolio of liquid enzymes to better serve the home care and I&I industry. With years of expertise, BASF has successfully integrated high-quality and high-performance enzymes into its product line, while ensuring sustainability and deep cleaning solutions. BASF has enhanced its range of liquid enzymes through the addition of lipase, cellulase and amylase offerings.
Building on its Lavergy product line, BASF has launched Lavergy L Pace, Lavergy C Care and Lavergy A Star. A liquid lipase product, Lavergy L Pace, has superior fat and oil stain removal ability at low temperatures. Lavergy C Care, a liquid care cellulase product, offers excellent fuzz and pill removal, best suited for cotton and cotton blend fabrics. The Lavergy A Star amylase biodegradable enzyme solution is effective in removing starch stains, offering a deeper clean.
BASF had already launched products like Lavergy M Ace, Lavergy C Bright and Lavergy Pro, building on its enzyme portfolio. With its in-depth technical know-how and innovation pipeline, BASF has positioned itself as one of the leaders in this industry.
BASFY stock has gained 9.7% over the past year compared with the industry’s 15.1% decline.
Image Source: Zacks Investment Research
BASFY’s Zacks Rank & Key Picks
BASFY currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Royal Gold, Inc. (RGLD - Free Report) ,Coeur Mining, Inc.(CDE - Free Report) andCarpenter Technology Corporation (CRS - Free Report) . While RGLD and CDE currently sport a Zacks Rank #1 (Strong Buy) each, CRS carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for RGLD’s current-year earnings is pegged at $7.47 per share, indicating a 42% year-over-year increase.Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 9%. RGLD’s shares have gained 18.7% in the past year.
The Zacks Consensus Estimate for CDE’s current-year earnings is pegged at 69 cents per share, implying a 283.3% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing once, with an average surprise of 136.2%.
The Zacks Consensus Estimate for CRS’ fiscal 2025 earnings is pegged at $7.28 per share, indicating a rise of 53.6% from year-ago levels. The company’s earnings beat the consensus estimate in each of the trailing four quarters. Its shares have gained 150.6% in the past year.